Cabaletta Bio (NASDAQ:CABA - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65), Zacks reports.
Cabaletta Bio Price Performance
Shares of NASDAQ:CABA traded down $0.08 during midday trading on Friday, reaching $1.11. The company's stock had a trading volume of 1,634,701 shares, compared to its average volume of 1,497,163. The business's fifty day simple moving average is $1.98 and its 200-day simple moving average is $2.89. Cabaletta Bio has a fifty-two week low of $1.08 and a fifty-two week high of $19.04. The company has a market capitalization of $56.32 million, a P/E ratio of -0.52 and a beta of 2.44.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on CABA shares. UBS Group decreased their target price on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday. Wells Fargo & Company decreased their price objective on Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday. Evercore ISI cut Cabaletta Bio from an "outperform" rating to an "inline" rating and dropped their target price for the stock from $15.00 to $6.00 in a report on Friday, December 20th. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a research note on Tuesday. Finally, Guggenheim reiterated a "buy" rating and issued a $23.00 price target on shares of Cabaletta Bio in a research report on Tuesday. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $21.00.
Check Out Our Latest Report on Cabaletta Bio
About Cabaletta Bio
(
Get Free Report)
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
See Also
Before you consider Cabaletta Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.
While Cabaletta Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
